SCHEMBL4606880

SCHEMBL4606880

CCC(=O)Nc1ccc(Oc2ccccc2NC(=O)Nc2ccccc2)cc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.57
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 3/20 0.51
HPGD P15428 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HSD17B10 Q99714 1/20 0.51
RCE1 Q9Y256 1/20 0.51
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
PYGM P11217 3/20 0.47
PYGL P06737 2/20 0.47
PKM P14618 2/20 0.47
MEN1 O00255 1/20 0.47
POLB P06746 2/20 0.47
ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4604249 0.92 POLB (0.54) ALDH1A1KDM4EHSD17B10PYGMPYGL
SCHEMBL4604961 0.89 ALDH1A1 (0.48) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL4603683 0.86 PYGM (0.62) KMT2ANPC1RAB9ASMN1; SMN2PYGM
SCHEMBL4604342 0.85 KDM4E (0.49) ALDH1A1KDM4EHSD17B10PYGMPYGL
SCHEMBL4603669 0.85 ALDH1A1 (0.53) KMT2AALDH1A1KDM4EHSD17B10SMN1; SMN2
SCHEMBL4606539 0.83 MTNR1B (0.50) ALDH1A1KDM4EHPGDHSD17B10PYGM
SCHEMBL4606525 0.83 CTSV (0.47) KMT2AALDH1A1KDM4EHSD17B10NPC1
SCHEMBL4605135 0.81 KDM4E (0.49) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL4619861 0.79 KDM4E (0.47) KMT2AALDH1A1KDM4EHSD17B10PKM
SCHEMBL4606034 0.79 IGF2BP2 (0.51) KMT2AALDH1A1KDM4EHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 KMT2A 3945/4885ALDH1A1 308/4885KDM4E 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.